- Date2024-09-10
Publication of Review Result of the Sixth Serious Illness (Cancer) Review Committee of 2023
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 6th Cancer Review Committee in 2023 on ‘Reimbursement criteria for drugs used for cancer patients’(Aug.30.) as follows.
|
Category |
product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Application for Healthcare Benefit Reimbursement |
Exkivity Cap. (Mobocertinib) |
Takeda Pharmaceuticals Korea Co., Ltd. |
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutation who have been previously treated with platinum-based chemotherapy |
Reimbursement criteria not to be established |
|
Rybrevant Inj. (Amivantamab) |
Janssen Korea, Inc |
Treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy treatment |
Reimbursement criteria not to be established | |
|
Pesco S.C. Inj. (Pertuzumab /Trastuzumab) |
Roche Korea, Inc |
Metastatic breast cancer/early breast cancer |
Reimbursement criteria to be established | |
|
Expand reimbursement scope |
Leclaza Tab. (Lazertinib) |
Yuhan co., Ltd. |
First-line treatment of patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 (L858R) substitution mutations |
Reimbursement criteria to be established |
|
Lorviqua Tab. (Lorlatinib) |
Pfizer Korea Inc. |
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer |
Reimbursement criteria to be established | |
|
Erbitux Injection (Cetuximab) |
Merck co., Inc |
Remove EGFR-positive conditions from the colorectal cancer notice |
Reimbursement criteria to be established |
* Pursuant to Article 5 and Article 5.2 of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service may notify the details of the reimbursement criteria and methods for drugs prescribed and administered to seriously ill patients that are designated and notified by the Minister of Health and Welfare after deliberation by the Serious Illness Review Committee. The reimbursement criteria for such drugs may be set differently according to clinical literature, domestic and foreign guidelines, and expert opinions within the scope of efficacy and effectiveness of the Ministry of Food and Drug Safety approval, and the reimbursement decision and criteria may change in the course of subsequent process.
